<DOC>
	<DOCNO>NCT01922102</DOCNO>
	<brief_summary>This study design evaluate efficacy safety two different dose regimen 0.5 mg ranibizumab give intravitreal injection comparison verteporfin PDT patient visual impairment due choroidal neovascularization secondary pathologic myopia ( PM )</brief_summary>
	<brief_title>Efficacy Safety Ranibizumab 0.5 v Veteporfin PDT Patients With Visual Impairment Due Choroidal Neovascularization Secondary Pathologic Myopia</brief_title>
	<detailed_description>This phase III , multi-center , randomize , double-masked , active-controlled study compare 0.5 mg ranibizumab vs. vPDT therapy . The study include 15 schedule visit 12 month , two additional visit ( 2a , 3a ) subset patient PK analysis perform . There 3 period study : Screening period-from Day -14 Baseline ; Treatment period-from Baseline Month 11 ; Follow-up period-from Month 11 Month 12 Patients enter 11 month Treatment period Visit 2 ( Day 1 ) eligibility criterion meet randomized three treatment group Group I ranibizumab 0.5 mg drive VA stability criterion Group II ranibizumab 0.5 mg driven disease activity criterion Group III vPDT ( randomization ratio 2:2:1 ) receive first treatment either ranibizumab injection sham vPDT sham injection active vPDT return clinical center within 7 day undergo safety assessment well assessment effect treatment evaluate investigator . The follow visit perform one month interval start Visit 4 continue Visit 14.At monthly visit ( at/from Month 2 group I , at/from Month 1 group II at/from Month 3 group III ) decision treatment make evaluate investigator base VA stability criterion disease activity criterion . At Month 3 ( visit 6 ) follow monthly visit three group one three option recommend evaluate investigator : ) ranibizumab 0.5 mg , b ) ranibizumab 0.5 mg + vPDT ; c ) vPDT . The treat investigator perform treatment base randomization masking requirement . At monthly visit , patient safety evaluation evaluate investigator prior study treatment , consist visual acuity measurement , ophthalmic examination evaluation adverse event vital sign . Routine hematology , chemistry , urinalysis profile obtain Visit 6 , 9 12 ( Month 3 , 6 9 ) . At Month 12 several procedure assessment perform require study completion visit .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Myopia</mesh_term>
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Neovascularization , Pathologic</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<mesh_term>Verteporfin</mesh_term>
	<criteria>Visual impairment due CNV secondary PM . Best correct visual acuity study eye &gt; 24 &lt; 78 ETDRS letter . High myopia ( &gt; 6D ) , anterioposterior elongation &gt; 26 mm ; posterior change compatible pathologic myopia . Either CNV location study eye : subfoveal , juxtafoveal , extrafoveal . Some preexist eye disorder systemic disease ; Blood pressure &gt; 150/90 mmHg Prior focal/grid laser macular area History treatment antiVEGF verteporfin PDT study eye Intravitreal treatment corticosteroid intraocular surgery within last 3 month study eye Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Pathologic myopia ( PM ) , choroidal neovascularization ( CNV ) , ranibizumab , verteporfin PDT , Brilliance</keyword>
</DOC>